Kailera Therapeutics Lands $400M from RTW Biotech for Obesity Focus

2 min read | October 03, 2024 09:15 AM PDT | By Team Kalkine Media

Google News:

Kailera Therapeutics Lands $400M from RTW Biotech for Obesity Focus — Image source: Shutterstock

Recent News

Is Public Service (NYSE:PEG) Still Worth Watching After Strong Results...

Is Hyatt Hotels (NYSE:H) Expansion Already Reflected In Market Valuati...

Jones Lang LaSalle (NYSE:JLL): Why Is Market Attention Growing?

Is Cummins (NYSE:CMI) Running Ahead Of Its Fundamentals?

Make Kalkine Media
My Trusted Source

Highlights:

RTW Biotech Opportunities Ltd has invested in Kailera Therapeutics, a startup focused on next-generation weight management treatments.

Kailera's lead product, KAI-9531, has shown positive results in Phase 2 trials for obesity and type 2 diabetes.

The $400 million Series A round was co-led by RTW Investments and other major venture firms, positioning Kailera as a leader in the obesity treatment market.

RTW Biotech Opportunities Ltd (LSE:RTWG) has announced its investment in Kailera Therapeutics, a Massachusetts-based startup focused on developing cutting-edge treatments for chronic weight management. Kailera successfully raised $400 million in a Series A funding round co-led by RTW Investments, alongside Atlas Venture, Bain Capital, and Lyra Capital.

Kailera is positioning itself as a leader in next-generation weight management therapies, with a robust portfolio of clinical-stage injectable and oral treatments. These therapies have demonstrated promising results as potential best-in-class treatments for chronic weight issues. The company's leading asset, KAI-9531, is a GLP-1/GIP receptor dual agonist, similar to Eli Lilly's popular obesity treatment tirzepatide (Mounjaro). This treatment has already shown positive results in Phase 2 trials in obesity and type 2 diabetes conducted in China.

Kailera secured the ex-China rights to four GLP-1 drugs from Jiangsu Hengrui Pharmaceuticals in May. The company’s experienced leadership team and strong pipeline of therapies are expected to make a significant impact on the weight management and metabolic disease market.

Roderick Wong, managing partner and chief investment officer at RTW Investments, expressed his optimism about the partnership. He noted that Kailera's innovative approach to chronic weight management, combined with its clinical success and strong management team, has the potential to greatly improve patient outcomes on a global scale.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.